Modulation of CD3-zeta as a marker of clinical response to IL-2 therapy in ovarian cancer patients
- 31 July 2004
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 94 (1) , 54-60
- https://doi.org/10.1016/j.ygyno.2004.03.032
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Expression of ζ in T Cells Prior to Interleukin-2 Therapy as a Predictor of Response and Survival in Patients with Ovarian CarcinomaCancer Biotherapy & Radiopharmaceuticals, 2002
- CD3‐ζchain expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patientsCancer, 2002
- Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes.Journal of Clinical Investigation, 1998
- Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinomaInternational Journal of Cancer, 1996
- Signal transduction by lymphocyte antigen receptorsCell, 1994
- Cancer of the OvaryNew England Journal of Medicine, 1993
- Survival After Phase II Treatment of Advanced Renal Cell Carcinoma with Taxol or High-Dose Interleukin-2Journal of Immunotherapy, 1993
- Second‐line chemotherapy for recurrent carcinoma of the ovaryCancer, 1993
- Alterations in Signal Transduction Molecules in T Lymphocytes from Tumor-Bearing MiceScience, 1992
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970